This Article Full Text Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Albers, J. W. Articles by Greene, D. A. Search for Related Content PubMed PubMed Citation Articles by Albers, J. W. Articles by Greene, D. A.

NEUROLOGY 1996;46:85-91
© 1996 American Academy of Neurology

Nerve conduction measures in mild diabetic neuropathy in the Early Diabetes Intervention Trial

The effects of age, sex, type of diabetes, disease duration, and anthropometric factors James W. Albers, MD, PhD, Morton B. Brown, PhD, Anders A.F. Sima, MD, PhD and Douglas A. Greene, MD

For The Tolrestat Study Group for the Early Diabetes Intervention Trial.
From the Departments of Biostatistics (Dr. Brown), Internal Medicine (Drs. Greene and Sima), Neurology (Dr. Albers), and Pathology (Dr. Sima), University of Michigan Medical Center, Ann Arbor, MI.
Supported by Wyeth-Ayerst Research.
Presented in part at the 47th annual meeting of the American Academy of Neurology, Seattle, WA, May 1995.
Received March 30, 1995. Accepted in final form May 1, 1995.
Address correspondence and reprint requests to Dr. James W. Albers, Department of Neurology, 1914 Taubman Center, University of Michigan Medical Center, Ann Arbor, MI 48109-0316.

Article abstract-We evaluated nerve conduction measures at baseline from 429 patients enrolled in a multicenter diabetic neuropathy study. We defined neuropathy by using recently proposed recommendations but included only patients who had measurable sural and peroneal responses and quantitative vibration thresholds. Patients with type II diabetes were older than type I patients (54.5 versus 39.1 years), were heavier (body mass index [BMI] of 30.9 versus 25.5 kg/m², and in general had lower evoked amplitudes. The effects of diabetes type upon nerve conduction measures disappeared when age and BMI were included in regression models. The men had lower amplitudes and conduction velocities and longer latencies than the women. The effect of gender was greatly reduced when height was included in the regression models, but gender continued to be a significant predictor of median sensory amplitude, most conduction velocities, and most latencies in these models. The relationships between nerve conduction measures and age, sex, and anthropometric factors were similar for patients with type II, but not those with type I, diabetes to the relationships reported for normal subjects. This may be a result of greater homogeneity with respect to degree of neuropathy for type II patients than for type I patients. These findings are important in designing and interpreting clinical studies of diabetic neuropathy.

NEUROLOGY 1996;46: 85-91

This article has been cited by other articles:

				J. W. Albers, D. H. Garabrant, J. L. Mattsson, C. J. Burns, S. S. Cohen, C. Sima, R. P. Garrison, R. J. Richardson, and S. Berent Dose-Effect Analyses of Occupational Chlorpyrifos Exposure and Peripheral Nerve Electrophysiology Toxicol. Sci., May 1, 2007; 97(1): 196 - 204. [Abstract] [Full Text] [PDF]

				C.-T. Shun, Y.-C. Chang, H.-P. Wu, S.-C. Hsieh, W.-M. Lin, Y.-H. Lin, T.-Y. Tai, and S.-T. Hsieh Skin denervation in type 2 diabetes: correlations with diabetic duration and functional impairments Brain, July 1, 2004; 127(7): 1593 - 1605. [Abstract] [Full Text] [PDF]

				M. J. Brown, S. J. Bird, S. Watling, H. Kaleta, L. Hayes, S. Eckert, and H. L. Foyt Natural Progression of Diabetic Peripheral Neuropathy in the Zenarestat Study Population Diabetes Care, May 1, 2004; 27(5): 1153 - 1159. [Abstract] [Full Text] [PDF]

				P. Thaisetthawatkul, E. L. Logigian, and D. N. Herrmann Dispersion of the distal compound muscle action potential as a diagnostic criterion for chronic inflammatory demyelinating polyneuropathy Neurology, November 26, 2002; 59(10): 1526 - 1532. [Abstract] [Full Text] [PDF]

				M. Backonja, A. Beydoun, K. R. Edwards, S. L. Schwartz, V. Fonseca, M. Hes, L. LaMoreaux, E. Garofalo, and for the Gabapentin Diabetic Neuropathy Study Group Gabapentin for the Symptomatic Treatment of Painful Neuropathy in Patients With Diabetes Mellitus: A Randomized Controlled Trial JAMA, December 2, 1998; 280(21): 1831 - 1836. [Abstract] [Full Text] [PDF]